#Sweden #Stockholm #Leqembi #BioArctic #Lars Lannfelt

BioArctic Founders to Sell Minor Shareholdings

In a recent announcement from BioArctic AB (publ), a Swedish biopharmaceutical company, it has come to light that the founders, Lars Lannfelt and Pär Gellerfors, are poised to divest a small percentage of their shareholdings. This move, which must be disclosed under the EU Market Abuse Regulation, marks a notable moment for the company and its stakeholders.

The decision to sell a part of their stakes is expected to generate interest among investors and the market at large, especially considering BioArctic's significant contributions to the field of neurodegenerative diseases. The announcement was made public on September 3, 2025, via the company's communication channels.

BioArctic is known for its innovative approaches to developing treatments that can alter the course of neurodegenerative disorders. Their flagship product, Leqembi®, has been recognized as the first drug that slows the progression of Alzheimer's disease, demonstrating a tangible impact on cognitive decline for patients in the early stages of this condition. This product has been collaboratively developed with Eisai, BioArctic's partner responsible for commercialization and regulatory tasks on a global scale.

Alongside Leqembi, BioArctic maintains a robust pipeline of research initiatives aimed at creating therapies for Parkinson's disease and Amyotrophic lateral sclerosis (ALS), among other neurodegenerative conditions. Many of these projects leverage the proprietary BrainTransporter™ technology, allowing for enhanced delivery and effectiveness of therapeutic antibodies.

The market will be closely observing the implications of the founders' divestment amid a backdrop of ongoing advancements in the pharmaceutical landscape. It prompts questions regarding the motivations behind the sale and whether this strategic move might be linked to broader operational goals or financial planning.

The impending sale is relatively minor, yet it could signal potential shifts in management's future investment in the company. Communication tools and investor relations have been prioritized to keep shareholders informed - including direct contact via Oskar Bosson, Vice President of Communications and Investor Relations.

As a publicly listed company on Nasdaq Stockholm under the ticker BIOA-B, BioArctic commands a significant presence in the biopharma sector, and moves from founding figures inevitably stir speculation.

In conclusion, while the announcement of Lars Lannfelt and Pär Gellerfors' intent to divest a minor portion of their holdings might seem straightforward, it is intertwined with a rich narrative of innovation, strategic development, and the future direction of BioArctic. Investors, patients, and the health community will be watching keenly for the subsequent moves from these key stakeholders as the company continues to push boundaries inTreatments for neurodegenerative diseases.